| Field Name |
Data Description |
| Test Name |
Quinidine |
| Code |
Quinidine Level. |
|
CPT Code |
80194 |
| Last Modified |
5/4/2018 10:05:00 AM |
| Test Name |
Quinidine. |
| Synonyms |
QUINID,TDM, DURAQU, QUINAG,CARDIO |
| Patient Preparation |
Collect just prior to next dose |
| Spec. Requirements |
Blood |
| Tube |
Red, or Dark Green (Heparin No Gel) |
| Collection Volume |
4.0 mL Red or Dark Green |
| Storage |
Refrigerated, Ambient, Frozen 14 days |
| Routine TAT |
|
| STAT TAT |
N/A |
| Days Test Performed |
|
| Performed by BHS |
None |
| See Availability |
|
| Reference Lab |
LabCorp of America |
| Reference Lab Code |
007831 Quinidine, Serum |
| Clinical Use |
This Class 1A drug is useful in both supraventricular and ventricular arrhythmias. It major uses are to maintain sinus rhythm after conversion of atrial flutter or fibrillation, to prevent ventricular tachycardia, and for long-term prophylaxis in patients with AV nodal reentrant tachycardia and automatic atrial tachycardia. Quinidine also has been used to prevent symptomatic premature supraventricular and ventricular complexes. Because it slows conduction and prolongs the refractory period of the accessory pathway and suppresses automaticity of ectopic pacemakers, quinidine may prevent recurrences of paroxysmal supraventricular tachycardia caused by reentry over a concealed pathway or AV reciprocating tachycardia associated with the Wolff-Parkinson-White syndrome. It also may slow the ventricular response to atrial flutter or fibrillation in the pre-excitation syndrome. Quinidine is often preferred to procainamide for long-term therapy because elevated antinuclear antibody titers and drug-induced lupus are common during prolonged therapy with procainamide. Optimal resampling time after change in dosage is one to two days. Biologic half-life is about six to eight hours. |
| Reference Range |
|
| Critical Value |
|
|
Component |
Quinidine |
|
Reference Range |
|
|
Critical Value |
|
 |
|
| Testing Sample Type |
Serum or Plasma |
| Min Lab Testing Volume |
0.5 mL |
| Special Handling |
Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant |
| Lab Notes |
Transfer separated serum or plasma to a plastic transport tube. Peak: quinidine sulfate: 11/2 hours after dose, quinidine gluconate: four hours after dose; trough: immediately prior to next dose; after change in dose: one to two days.
|
| Methodology |
IA - Immunoassay |
| Limitations |
Reject Criteria: Gel-barrier tube; severe hemolysis; lipemia; icteric specimen |
